Overview

A Phase 2a Study to Evaluate the Safety and Efficacy of Cannabidiol Only as Maintenance Therapy and Steroid Sparing in Patients With Stable Autoimmune Hepatitis

Status:
Terminated

Trial end date:
2020-03-01

Target enrollment:

Participant gender:

Summary

Subjects with stable autoimmune hepatitis disease currently being administered corticosteroids with or without azathioprine (AZA) treatment will be be treated with Cannabidiol instead of standard of care treatment with corticosteroids

Phase:

Phase 2

Details

Lead Sponsor:

Stero Biotechs Ltd.

Treatments:

Cannabidiol
Epidiolex